Search clinical trials for: GSK2633771

Total 1 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; National...

Active, not recruiting

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States

3

Subscribe